All In Biotech

Drug Trial Radar · NCT06916793

A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia

A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-group Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-843 in Male Patients With Androgenetic Alopecia

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 288 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

288

Planned (sponsor's estimate)

Start

Apr 8, 2025

Primary completion

Sep 30, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Chong Kun Dang PharmaceuticalIndustry
Sponsor type
Industry
First posted
Apr 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia

Conditions

  • Androgenetic Alopecia

Interventions

  • CKD-843 dose#1Drug

    IM injection every 3 months for 12 months

  • CKD-843 dose#2Drug

    IM injection every 3 months for 12 months

  • Placebo of CKD-843 doseDrug

    IM injection every 3 months for 12 months

  • Dutasteride CapsulesDrug

    oral, once daily, 12 months

  • Placebo of Dutasteride CapsuleDrug

    oral, once daily, 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total number of hair ChangesTime frame: Baseline, Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.